Metabolic Longevity · 2mg × 10 vials
In plain terms: Thymosin Alpha-1 is a research compound - oral, long-acting and well studied.
Thymosin Alpha-1 is a 28-amino-acid peptide naturally produced by the thymus, the gland that "trains" T-cells. As people age (and especially during chronic infection, sepsis, cancer, or post-viral syndromes like long-COVID), thymic output collapses and naive T-cell production tanks. Tα1 acts as a thymic replacement signal: it pushes immature thymocytes through maturation into functional CD4+ and CD8+ T-cells, activates natural killer (NK) cells and dendritic cells, and upregulates Toll-like receptor signaling (primarily TLR9 and TLR2) on antigen-presenting cells. Net effect is a rebalancing of immune function, it pushes a depressed immune system back toward competent Th1-style response (cell-mediated, antiviral, antitumor) while simultaneously dampening the runaway inflammation seen in sepsis and cytokine storm. This dual action (boost where suppressed, calm where over-firing) is why the same molecule is used both for chronic viral hepatitis (where the immune system needs to wake up and clear the virus) and for sepsis/COVID ICU patients (where it needs to stop killing the host with cytokines). Approved as Zadaxin in 35+ countries for HBV, HCV, and as an immune adjuvant; in the US it remains research-use only.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
This is the Zadaxin label dose for HBV/HCV and is the same dose used in most COVID-ICU trials. It's the universal starting point for long-COVID, chronic Lyme, post-viral fatigue, and immunocompromised support. Effect curve is slow: most users describe a subtle "lifting" of post-viral fatigue and brain fog around weeks 3-6, with more sustained energy by weeks 8-12. Don't expect a dramatic week-1 response.
Intermediate band is for users who've run the standard protocol 8-12 weeks and want to push harder, or who are stacking for an active immune challenge (chronic Lyme, mold illness, EBV reactivation, post-COVID flare). Some practitioners (Patterson protocol for long-COVID) pulse Tα1 alongside maraviroc/statin combos at this intermediate intensity. Stacks well at this band with LL-37 for active infection and NAD+ for mitochondrial recovery.
Advanced dosing is used in oncology adjunctive settings (typically alongside chemo cycles, dosed on the days around treatment to preserve immune function), in HBV/HCV combo protocols (with interferon or DAAs), and in sepsis / severe acute infection. Outside those acute clinical contexts, advanced dosing is rarely necessary for outpatient immune support. The 6.4 mg/day signal comes from sepsis trial protocols, not from chronic outpatient use. If a customer is asking about advanced dosing for chronic fatigue or long-COVID, the right answer is almost always "stay at 1.6 mg 2x/wk longer and add NAD+/MOTS-c" rather than push the dose.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
](https://pmc.ncbi.nlm.nih.gov/articles/PMC2750086/) - comprehensive mechanism + clinical applications review by the discoverer of Tα1
Read study ↗PubMedCamerini & Garaci, Historical review on the discovery of thymosin alpha 1 (PMC4859321)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4859321/) - discovery history, T-cell maturation mechanism, regulatory approvals across 35+ countries
Read study ↗PubMedThymosin alpha 1 therapy in chronic hepatitis B, meta-analysis (PMID 11737030)](https://pubmed.ncbi.nlm.nih.gov/11737030/) - HBV response rates ~25-40% sustained virologic response vs ~10-15% untreated controls
Read study ↗PubMedThymosin alpha 1 in HCV combination therapy (PMC3539291)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3539291/) - HCV combination data with interferon and ribavirin
Read study ↗PubMedLiu et al, Thymosin Alpha 1 reduces 28-day mortality in severe sepsis (PMID 23979484)](https://pubmed.ncbi.nlm.nih.gov/23979484/) - RCT, Tα1 reduced sepsis 28-day mortality from 35% to 26% (absolute reduction 9%, p=0.06 trending)
Read study ↗PubMedWei Liu et al, Thymosin alpha 1 reduces mortality in severe COVID-19 (Clin Infect Dis 2020, PMC7184460)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7184460/) - retrospective cohort, 76 severe COVID patients, Tα1 reduced 28-day mortality from 30% to 11%
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Mild fatigue / "immune flare" in week 1-2: some users describe a brief "feeling like getting sick" sensation as the immune system reactivates, resolves on its own
Injection site stinging: more often reported on abdomen, less on thigh
Subtle effect: most common complaint is that effects are too subtle to feel; long-COVID users in particular report the benefit shows up as "I didn't crash this month" rather than as a dramatic energy surge
Vivid dreams / sleep changes: occasional report, not consistent
"Lyme/mold herx" (Jarisch-Herxheimer-like response): some chronic-infection users report a transient flare in symptoms in the first 2-3 weeks, attributed to immune reactivation against latent infection; usually resolves and is interpreted as a working signal
- Divergence: Clinical trials show essentially no symptom burden from Tα1 alone; community in chronic Lyme/long-COVID contexts reports a real herx-like response in week 1-3 in ~15-25% of users. This is a population-effect (sick population reactivating immunity), not a drug toxicity, and is generally taken as a positive sign that the peptide is doing…
Route: SubQ injection (the FDA Zadaxin label is SubQ; IV has been used in ICU trials but is not standard for outpatient use)
Injection site: abdomen, outer thigh, or back of upper arm; rotate sites. Some users report less injection-site stinging on the thigh vs abdomen.
Storage: refrigerated, ~14-28 days after reconstitution. Tα1 is more stable than BPC/TB but still degrades, don't keep a reconstituted vial past a month. Unreconstituted lyophilized powder is shelf-stable at room temp for short windows but should be refrigerated for long storage.
Notes: Zadaxin label dosing is 1.6 mg twice weekly with at least 3-4 days between doses (typical pattern: Monday + Thursday, or Tuesday + Friday). Inject on consistent days. No need to time around meals. Some clinical protocols (sepsis, COVID-ICU) used daily dosing at 1.6-3.2 mg for short acute windows, but outpatient/chronic use is always the 2x/wk pattern.